{
  "$schema": "folio-library-entry/v1",
  "id": "10665-44796",
  "blocks": [
    {
      "id": "library/10665-44796/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Pandemic influenza\npreparedness Framework \nfor the sharing of influenza viruses \nand access to vaccines and \nother benefits\nPandemic influenza\npreparedness Framework \nfor the sharing of influenza viruses \nand access to vaccines and \nother benefits\nii\n© World Health Organization 2011\nAll rights reserved. Publications of the World Health Organization are available on the WHO \nweb site (www.who.int) or can be purchased from WHO Press, World Health Organization, \n20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: \nbookorders@who.int). Requests for pe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's 2011 Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits. It contains the title and copyright pages and contents, and begins World Health Assembly resolution WHA64.5 of 24 May 2011, which considered the report of the Open-Ended Working Group of Member States.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHA 64.5 Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccine sand other benefits",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-000-wha-645-pandemic-influenza-preparedness-sharing.md",
      "narrative": null,
      "content": "vaccines and other benefits;1\nAcknowledging the work of the Co-Chairs and the Bureau of the Open-Ended \nWorking Group;\nWelcoming the outcome of the Open-Ended Working Group of Member States \non Pandemic Influenza Preparedness: sharing of influenza viruses and access to \nvaccines and other benefits in elaborating the Pandemic Influenza Preparedness \nFramework for sharing of influenza viruses and access to vaccines and other benefits \n(the “Pandemic Influenza Preparedness Framework”);\nRecognizing the role of industry as an important contributor to technology innovation \nand transfer in addressin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Completes resolution WHA64.5, in which the Health Assembly welcomes and adopts the Pandemic Influenza Preparedness Framework and asks the Director-General to implement it and report every two years through the Executive Board.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Principles",
      "pageStart": 9,
      "pageEnd": 12,
      "target": "../sections/sec-001-1-principles.md",
      "narrative": null,
      "content": "1.\t Principles\nIn relation to pandemic influenza preparedness: sharing of influenza viruses and \naccess to vaccines and other benefits, WHO Member States:\n(1)\t\nrecall World Health Assembly resolution WHA60.28 on pandemic influenza \npreparedness: sharing of influenza viruses and access to vaccines and other \nbenefits;\n(2)\t\nnote the continuing risk of an influenza pandemic with potentially devastating health, economic and social impacts, particularly for developing countries, \nwhich suffer a higher disease burden and are more vulnerable; \n(3)\t\nrecognize that Member States have a commitment to sh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the Framework's principles, in which Member States recall resolution WHA60.28 and note the continuing risk of a devastating influenza pandemic, especially for developing countries. They affirm the value of rapid virus sharing alongside fair access to vaccines and benefits, and recognize the need for technology transfer and financing that makes vaccines and medicines affordable for developing countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Objective",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-002-2-objective.md",
      "narrative": null,
      "content": "2.\t Objective\nThe objective of the Pandemic Influenza Preparedness Framework is to improve \npandemic influenza preparedness and response, and strengthen the protection \nagainst the pandemic influenza by improving and strengthening the WHO global \ninfluenza surveillance and response system (“WHO GISRS”), with the objective \nof a fair, transparent, equitable, efficient, effective system for, on an equal footing: \n(i)\t\nthe sharing of H5N1 and other influenza viruses with human pandemic \npotential; and\n(ii)\t\naccess to vaccines and sharing of other benefits.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States the Framework's objective: to improve pandemic preparedness and response by strengthening WHO's global influenza surveillance and response system, with a fair and transparent system for sharing H5N1 and other potentially pandemic viruses and for access to vaccines and other benefits.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-003-3-scope.md",
      "narrative": null,
      "content": "3.\t Scope\n3.1\t\nThis Framework applies to the sharing of H5N1 and other influenza viruses \nwith human pandemic potential and the sharing of benefits.\n3.2\t\nThis Framework does not apply to seasonal influenza viruses or other non-\ninfluenza pathogens or biological substances that may be contained in clinical \nspecimens shared under this Framework.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the Framework's scope as the sharing of H5N1 and other influenza viruses with human pandemic potential and related benefits, excluding seasonal influenza and other pathogens.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions and use of terms",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-004-4-definitions-and-use-of-terms.md",
      "narrative": null,
      "content": "4.\t Definitions and use of terms\nFor the purpose of this Framework, the following terms have the meanings assigned \nto them below.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the section defining terms used in the Framework.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pandemic influenza preparedness biological materials or PIP biological materials",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-005-41-pandemic-influenza-preparedness-biological-ma.md",
      "narrative": null,
      "content": "materials\n\t\n“PIP biological materials”,1 for the purposes of this Framework (and its \nannexed Standard Material Transfer Agreements (SMTAs) and terms of reference (TORs)) and the Influenza Virus Tracking Mechanism (IVTM), includes \nhuman clinical specimens,2 virus isolates of wild type human H5N1 and other influenza viruses with human pandemic potential; and modified viruses \nprepared from H5N1 and/or other influenza viruses with human pandemic \npotential developed by WHO GISRS laboratories, these being candidate vaccine viruses generated by reverse genetics and/or high growth re-assortment.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines 'PIP biological materials' as clinical specimens, wild-type and modified isolates of H5N1 and other potentially pandemic influenza viruses, and their extracted RNA and cDNA covering whole gene coding regions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Other technical terms",
      "pageStart": 14,
      "pageEnd": 16,
      "target": "../sections/sec-006-42-other-technical-terms.md",
      "narrative": null,
      "content": "“Genetic sequences” means the order of nucleotides found in a molecule of \nDNA or RNA. They contain the genetic information that determines the biological characteristics of an organism or a virus.\n\t\n“Reference reagents” are biological or chemical substances or organisms and \nparts thereof used in diagnostic or surveillance activities. They are rigorously \ncharacterized and shown to be suitable for use as standards in order to compare and validate results of analyses obtained in different laboratories.\n1\t OPERATIONAL EXEMPTION: materials shared within the WHO GISRS or with other laboratories s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines further technical terms used in the Framework, such as genetic sequences, reference reagents, candidate vaccine viruses and wild-type influenza viruses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Institutions, organizations and entities",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-007-43-institutions-organizations-and-entities.md",
      "narrative": null,
      "content": "“Essential regulatory laboratories” means influenza laboratories designated by \nWHO located in, or associated with, national regulatory agencies and which \nhave a critical role at the global level for developing, regulating and standardizing human influenza vaccines. Such laboratories participate in the WHO \nGISRS in accordance with their corresponding terms of reference.\n\t\n“Influenza vaccine, diagnostic and pharmaceutical manufacturers” means \npublic or private entities including academic institutions, government owned \nor government subsidized entities, nonprofit organizations or commercial",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the institutions involved, such as essential regulatory laboratories, influenza vaccine, diagnostic and drug manufacturers and the laboratories that make up WHO's global influenza surveillance and response system.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Other terms",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-008-44-other-terms.md",
      "narrative": null,
      "content": "“Advisory Group” means the Group referred to in section 7.2 of this Framework.\n\t\n“Affected country” means countries with laboratory confirmed cases of H5N1, \nor other influenza viruses with human pandemic potential.\n\t\n“Director-General” means the Director-General of the World Health Organization.\n\t\n“Least-developed country” means those countries that are periodically classified as least-developed countries by the United Nations Committee for Development Policy.\n\t\n“Originating laboratory” means a National Influenza Centre or other authorized laboratory that initially sends PIP biological materi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines other terms used in the Framework, including Advisory Group, affected country, least-developed country and the PIP vaccine stockpile.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pandemic influenza preparedness system for sharing of H5N1 and other influenza viruses with human pandemic potential",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-009-5-pandemic-influenza-preparedness-system-for-sha.md",
      "narrative": null,
      "content": "for sharing of H5N1 and other influenza \nviruses with human pandemic potential",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading for the section on the system for sharing H5N1 and other potentially pandemic influenza viruses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "General",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-010-51-general.md",
      "narrative": null,
      "content": "5.1.1\t\nMember States, through their National Influenza Centres and Other \nauthorized laboratories, should in a rapid, systematic and timely manner \nprovide PIP biological materials from all cases of H5N1 and other influenza \nviruses with human pandemic potential, as feasible, to the WHO Collaborating Centre on Influenza or WHO H5 Reference Laboratory of the originating Member State’s choice.\n5.1.2\t\nBy providing PIP biological materials from National Influenza Centres and \nOther authorized laboratories to WHO Collaborating Centres on Influenza and WHO H5 Reference Laboratories as set out in sec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out that Member States should rapidly share PIP biological materials from all cases of H5N1 and other potentially pandemic influenza through their national laboratories with a WHO Collaborating Centre or H5 Reference Laboratory of their choice. It notes they may also share bilaterally if WHO laboratories receive the materials with priority.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Genetic sequence data",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-011-52-genetic-sequence-data.md",
      "narrative": null,
      "content": "5.2.1\t\nGenetic sequence data, and analyses arising from that data, relating to \nH5N1 and other influenza viruses with human pandemic potential should \n13\nbe shared in a rapid, timely and systematic manner with the originating \nlaboratory and among WHO GISRS laboratories.\n5.2.2\t\nRecognizing that greater transparency and access concerning influenza \nvirus genetic sequence data is important to public health and there is a \nmovement towards the use of public-domain or public-access databases \nsuch as Genbank and GISAID respectively; and\n5.2.3\t\nRecognizing that in some instances the publication of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for rapid sharing of genetic sequence data on potentially pandemic influenza viruses with originating laboratories and within GISRS, and asks the Director-General to seek advice on handling such data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Traceability and reporting mechanisms",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-012-53-traceability-and-reporting-mechanisms.md",
      "narrative": null,
      "content": "5.3.1\t\nThe Director-General, in consultation with the Advisory Group,1 will put \nin place in a timely manner a transparent traceability mechanism that uses \nan electronic system in order to track in real time the movement of PIP \nbiological materials into, within, and out of the WHO GISRS.\n5.3.2\t\nTo ensure that rapid, systematic and timely feedback is provided to Originating laboratories and Member States, the Director-General will also \ninclude in the traceability mechanism and associated electronic reporting \nsystems a request that WHO Collaborating Centres, H5 Reference Laboratories and Ess",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits the Director-General to set up an electronic system to track in real time the movement of PIP biological materials into, within and out of GISRS, and to give feedback to originating laboratories and countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Standard Material Transfer Agreements",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-013-54-standard-material-transfer-agreements.md",
      "narrative": null,
      "content": "5.4\t Standard Material Transfer Agreements\n5.4.1\t\nThe Standard Material Transfer Agreement 1 (SMTA 1) in Annex 1 will \nbe used to cover all transfers of PIP biological materials within the WHO \nGISRS for the duration of its applicability.\n5.4.2\t\nThe Director-General will, using the Standard Material Transfer Agreement 2 (SMTA 2) in Annex 2, enter into agreements with entities outside \nthe WHO GISRS. Such agreements will cover all transfers of PIP biological \nmaterials to recipients for their duration.\n15\n6.\t Pandemic influenza preparedness\nbenefit sharing system",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that Standard Material Transfer Agreement 1 governs transfers of PIP biological materials within GISRS, and that SMTA 2 will be used for agreements with entities outside it.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "General",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-014-60-general.md",
      "narrative": null,
      "content": "6.0.1\t\nMember States should, working with the WHO Secretariat, contribute to \na pandemic influenza benefit-sharing system and call upon relevant institutions, organizations, and entities, influenza vaccines, diagnostics and \npharmaceutical manufacturers and public health researchers to also make \nappropriate contribution to this system.\n6.0.2\t\nThe PIP Benefit Sharing System will operate to:\n(i)\t\nprovide pandemic surveillance and risk assessment and early warning \ninformation and services to all countries;\n(ii)\t provide benefits, including, where appropriate, capacity building in \npandemic surv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the general aims of the PIP benefit-sharing system, to which Member States and manufacturers should contribute, covering surveillance and risk assessment, access to vaccines and supplies, and capacity building and technology transfer for receiving countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pandemic influenza preparedness benefit sharing system",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-015-6-pandemic-influenza-preparedness-benefit-sharin.md",
      "narrative": null,
      "content": "The pandemic influenza preparedness Benefit Sharing System will include \nthe elements set out in the remainder of this part.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that the benefit-sharing system includes the elements set out in the rest of the section.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO Coordination of pandemic influenza preparedness and response",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-016-61-who-coordination-of-pandemic-influenza-prepar.md",
      "narrative": null,
      "content": "WHO will coordinate influenza pandemic preparedness and response in accordance with applicable International Health Regulations (2005) provisions and this \n16\nFramework. As regards the benefits outlined in this Framework, WHO should pay \nparticular attention to policies and practices that promote the fair, equitable and \ntransparent allocation of scarce medical resources (including, but not limited to, \nvaccines, antivirals and diagnostic materials) during pandemics based on public \nhealth risk and needs, including the epidemiology of the pandemic. During inter-\npandemic periods, WHO will work",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that WHO will coordinate pandemic preparedness and response under the International Health Regulations (2005), with attention to fair and transparent allocation of scarce vaccines, antivirals and diagnostics according to public health risk and need.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pandemic risk assessment and risk response",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-017-62-pandemic-risk-assessment-and-risk-response.md",
      "narrative": null,
      "content": "6.2.1\t\nWHO GISRS laboratories will make available to the WHO Secretariat and \nthe originating Member State, in a rapid, systematic and timely manner, \na summary report of laboratory analyses and on request any other available information required regarding PIP biological materials to enable \nthe affected countries and in particular, developing countries, to make an \neffective and meaningful risk response.\n6.2.2\t\nWHO will provide information on risk response including, but not limited \nto, information on development of vaccines, candidate virus and effective \nantivirals to all affected countrie",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits GISRS laboratories to share laboratory analysis reports with WHO and originating countries, and WHO to support countries, especially developing ones, in pandemic risk assessment and response through information and technical assistance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Provision of PIP candidate vaccine viruses",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-018-63-provision-of-pip-candidate-vaccine-viruses.md",
      "narrative": null,
      "content": "6.3.1\t\nThe Director-General will ensure that WHO Collaborating Centres on \nInfluenza/H5 Reference Labs and Essential Regulatory Laboratories, as \nagreed in the terms of reference, provide PIP candidate vaccine viruses \nupon request: \n(i)\t\nto influenza vaccine manufacturers on a no preference basis;\n(ii)\t at the same time to the laboratories of originating and other Member \nStates; \n(iii)\t to any other laboratory.\n17\n6.3.2\t\nAny entity receiving PIP candidate vaccine viruses will meet appropriate \nbiosafety guidelines (WHO Laboratory Biosafety Manual, 3rd edition) and \nemploy laboratory protecti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out that WHO laboratories will provide candidate vaccine viruses on request to manufacturers without preference and at the same time to Member States' laboratories, under appropriate biosafety rules.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Provision of diagnostic reagents and test kits",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-019-64-provision-of-diagnostic-reagents-and-test-kit.md",
      "narrative": null,
      "content": "6.4.1\t\nWHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories, working with the WHO Secretariat, will continue to make available to National Influenza Centres and \nOther authorized laboratories, without charge, supplies of noncommercial \ndiagnostic reagents and test kits for the identification and characterization \nof clinical specimens of influenza.\n6.4.2\t\nInfluenza diagnostic manufacturers receiving PIP biological materials are \nurged to make available to WHO GISRS laboratories, without charge or at \nconcessional and/or preferential rates,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits WHO laboratories to supply free non-commercial diagnostic reagents and test kits to national laboratories and urges diagnostic manufacturers to provide them free or at reduced cost.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Provision of reference reagents for potency determination of vaccines",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-020-65-provision-of-reference-reagents-for-potency-d.md",
      "narrative": null,
      "content": "6.5.1\t\nEssential Regulatory Laboratories will continue to provide, upon request, \nreference reagents for potency determination of vaccines against H5N1 \nand other viruses of human pandemic potential to national regulatory \nlaboratories and influenza vaccine manufacturers of all Member States. \n6.5.2\t\nEssential Regulatory Laboratories will continue to provide upon request, \ntraining in quality control of vaccines against H5N1 and other viruses of \nhuman pandemic potential to national regulatory laboratories of all Member States.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits essential regulatory laboratories to provide reference reagents for vaccine potency testing and training in vaccine quality control to all Member States on request.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Laboratory and influenza surveillance capacity building",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-021-66-laboratory-and-influenza-surveillance-capacit.md",
      "narrative": null,
      "content": "6.6.1\t\nUpon request, Member States with advanced laboratory and influenza \nsurveillance capacity are urged to continue to work with WHO and other \nMember States, particularly developing countries, to develop national laboratory and influenza surveillance capacity, including: \n(i)\t\nto conduct early detection, isolation and characterization of viruses; \n(ii)\t to participate in pandemic risk assessment and response;\n(iii)\t to develop research capacity related to influenza; \n(iv)\t to achieve technical qualifications for consideration of laboratories \nas National Influenza Centres, WHO H5 Reference",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Urges Member States with advanced capacity to help others, especially developing countries, build laboratory and influenza surveillance capacity, including virus detection and research.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Regulatory capacity building",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-022-67-regulatory-capacity-building.md",
      "narrative": null,
      "content": "6.7\t Regulatory capacity building\n6.7.1\t\nUpon request, Member States with advanced regulatory capacity should \nimprove and strengthen the work that has been undertaken by Member \nStates with WHO, particularly in developing countries, to strengthen the \ncapacity of regulatory authorities to carry out the necessary measures for \nthe rapid approval of safe and effective human influenza vaccines, diagnostics and pharmaceutical products, including products developed from \nthe use of PIP biological materials, especially those derived from new sub-\ntypes of influenza viruses. \n6.7.2\t\nMember States sh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls on Member States with advanced regulatory capacity to help strengthen regulators in developing countries so that pandemic influenza vaccines, diagnostics and medicines can be approved rapidly, and to share information on approvals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antivirals stockpiles",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-023-68-antivirals-stockpiles.md",
      "narrative": null,
      "content": "6.8.1\t\nThe Director-General will continue to work with other multilateral agencies, donors, international philanthropic organizations/entities, private \nfoundations, and other potential partners, including institutions, organizations and entities and in particular influenza vaccine, diagnostic and \npharmaceutical manufacturers, to seek commitments for contributions, \nmaintain and further develop a stockpile of antiviral medicines and associated equipment for use in containment of outbreaks of H5N1 and other \ninfluenza viruses with human pandemic potential.\n6.8.2\t\nThe Director-General will cont",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits the Director-General to work with partners and manufacturers to maintain a WHO stockpile of antiviral medicines and to seek expert advice on its size and use.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pandemic influenza preparedness vaccine stockpile",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-024-69-pandemic-influenza-preparedness-vaccine-stock.md",
      "narrative": null,
      "content": "6.9.1\t\nThe Director-General will establish and maintain a stockpile of vaccines \nfor H5N1 and other influenza viruses with human pandemic potential and \nassociated equipment, including syringes, needles and applicators, consistent with expert guidance.\n19\n6.9.2\t\nThe WHO stockpile will initially include 150 million doses of H5N1 vaccine for use in accordance with expert guidance including the Strategic \nAdvisory Group of Experts on immunization (SAGE). Indicatively: \n(i)\t\n50 million doses will be for use in affected countries, according to \npublic health risk and need, to assist in containing t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits the Director-General to establish a WHO stockpile of vaccines for H5N1 and other potentially pandemic viruses, initially 150 million doses, with related equipment. It covers allocation according to expert guidance and plans for deploying the vaccines to affected countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Access to vaccines in the inter-pandemic period for developing countries",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-025-610-access-to-vaccines-in-the-inter-pandemic-per.md",
      "narrative": null,
      "content": "6.10.1\t\nSeparately from measures to support the WHO PIP vaccine stockpile set \nout in section 6.9 above:\n(i)\t\nMember States should urge influenza vaccine manufacturers to set \naside a portion of each production cycle of vaccines for H5N1 and other influenza viruses with human pandemic potential for stockpiling \nand/or use, as appropriate, by developing countries; and \n(ii)\t Member States should continue to work with each other, with the \nDirector-General and with influenza vaccine manufacturers, with the \n20\naim of ensuring that adequate quantities of vaccines for H5N1 and \nother influenza vir",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Urges manufacturers to reserve part of each production cycle of H5N1 and other potentially pandemic vaccines for developing countries and seeks timely access for them at tiered prices.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Access to pandemic influenza vaccines",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-026-611-access-to-pandemic-influenza-vaccines.md",
      "narrative": null,
      "content": "6.11.1\t\nMember States should urge vaccine manufacturers to set aside a portion of \neach production cycle of pandemic influenza vaccine for use by developing \ncountries; and \n6.11.2\t\nThe Director-General, consulting Member States and the Advisory Group, \nwill convene an expert group to continue to develop international mechanisms, including existing ones, for the production and distribution of \ninfluenza vaccines on the basis of public health risk and needs during a \npandemic, for consideration by the World Health Assembly in 2010.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Urges manufacturers to reserve part of pandemic vaccine production for developing countries and calls for an expert group to develop mechanisms for distributing vaccines by public health risk and need.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tiered pricing",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-027-612-tiered-pricing.md",
      "narrative": null,
      "content": "As a measure to improve the affordability for developing countries of pandemic \ninfluenza vaccines and vaccines for H5N1 and other influenza viruses with human \npandemic potential, and antivirals, Member States should urge influenza vaccine \nand antiviral manufacturers individually to implement tiered pricing for these vaccines and antivirals. As part of this approach, influenza vaccine and antiviral manufacturers individually should be urged to consider the income level of the country, \nand negotiate with the national authorities of the recipient country, in arriving at the \nprice to be appli",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Urges vaccine and antiviral manufacturers to apply tiered pricing that takes account of country income levels, with attention to the least developed countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Technology transfer",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-028-613-technology-transfer.md",
      "narrative": null,
      "content": "6.13.1\t\nThe Director-General will continue to work closely with Member States \nand influenza vaccine manufacturers to implement the WHO Global Pandemic Influenza Action Plan to Increase Vaccine Supply, including its strategies to build new production facilities in developing and/or industrialized \ncountries and through transfer of technology, skills and know-how. \n6.13.2\t\nMember States should urge influenza vaccine, diagnostic and pharmaceutical manufacturers to make specific efforts to transfer these technologies \nto other countries, particularly developing countries, as appropriate. \n6.13.3",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Commits WHO to continue the Global Pandemic Influenza Action Plan to Increase Vaccine Supply, including new production facilities and transfer of technology and know-how. It urges manufacturers to support technology transfer and suggests countries consider seasonal influenza vaccination to sustain local production.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Sustainable and innovative financing mechanisms",
      "pageStart": 27,
      "pageEnd": 29,
      "target": "../sections/sec-029-614-sustainable-and-innovative-financing-mechani.md",
      "narrative": null,
      "content": "6.14.1\t\nWith a view to ensuring the sustainable financing of the PIP Benefit Sharing System, particularly for developing countries; and \n6.14.2\t\nHaving regard to the desirability of all Member States and recipients of PIP \nbiological materials contributing to the PIP Benefit Sharing System, financially or in kind, according to their capacity and over time; \n6.14.3\t\nInfluenza vaccine, diagnostic and pharmaceutical manufacturers, using \nthe WHO GISRS, will make an annual partnership contribution to WHO \nfor improving global pandemic influenza preparedness and response. It \nis decided that the su",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out financing for the benefit-sharing system, including an annual Partnership Contribution from manufacturers that use GISRS, its use for preparedness and response and how it is managed. It also urges Member States to increase support for laboratory and surveillance capacity in developing countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Governance and review",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-030-7-governance-and-review.md",
      "narrative": null,
      "content": "7.\t Governance and review",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading for the section on governance and review of the Framework.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "General",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-031-71-general.md",
      "narrative": null,
      "content": "General\n7.1.1\t\nThe implementation of this Framework will be overseen by the World \nHealth Assembly with advice from the Director-General. \n7.1.2\t\nAn oversight mechanism is hereby established, which includes the World \nHealth Assembly, the Director-General and the independent “Advisory \nGroup”, established in connection with the Interim Statement of November 2007, and composed of international experts serving the Organization \nexclusively. Respectively, their function will be as follows: \n(i)\t\nThe Health Assembly, consistent with the Organization’s Constitutional function to act as the “directi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out that the World Health Assembly oversees the Framework with advice from the Director-General, through an oversight mechanism that includes an independent Advisory Group of international experts.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Advisory Group",
      "pageStart": 29,
      "pageEnd": 30,
      "target": "../sections/sec-032-72-advisory-group.md",
      "narrative": null,
      "content": "provide evidence-based reporting, assessment and recommendations \nregarding the functioning of the Framework. The Advisory Group, \nconsistent with WHO practice regarding such independent expert \nbodies, will advise the Director-General but will not itself engage in \nadministrative functions, such as the recognition, or withdrawal of \nrecognition, of technical institutions, nor will it have a public role, except as authorized. \n7.2\t Advisory Group\n7.2.1\t\nThe Director-General will maintain the Advisory Group, referenced in \nsection  7.1.2 above, to monitor and provide guidance to strengthen the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the Advisory Group's role in monitoring and advising on the Framework without administrative or public functions, its membership and reporting, and asks for a report to the Health Assembly in 2012 on its future mandate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Governance and review of terms of reference for WHO global influenza surveillance and response system (GISRS) laboratories",
      "pageStart": 30,
      "pageEnd": 33,
      "target": "../sections/sec-033-73-governance-and-review-of-terms-of-reference-f.md",
      "narrative": null,
      "content": "7.3.1\t\nThe terms of reference of the WHO Collaborating Centres on Influenza, \nWHO H5 Reference Laboratories, National Influenza Centres and Essen\n25\ntial Regulatory Laboratories should be developed in accordance with the \nguiding principles outlined in Annex 4 to this Framework.\n7.3.2\t\nThe Director-General, in consultation with the Advisory Group and competent authorities in Member States, and the WHO Collaborating Centres, \nWHO H5 Reference Laboratories, National Influenza Centres, and Essential Regulatory Laboratories, will review periodically the terms of reference \nof the institutions and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers terms of reference for GISRS laboratories, a review of the definition of PIP biological materials and a full review of the Framework by 2016, with proposals to the Health Assembly in 2017.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexes",
      "pageStart": 33,
      "pageEnd": 43,
      "target": "../sections/sec-034-annexes.md",
      "narrative": null,
      "content": "Annexes\n29\nAnnex 1\nStandard Material Transfer Agreement 1 (SMTA 1)\nStandard Material Transfer Agreement within the WHO global \ninfluenza surveillance and response system (GISRS )\nIn furtherance of the Pandemic Influenza Preparedness Framework for the sharing \nof influenza viruses and access to vaccines and other benefits (the “Framework”), \nthis Standard Material Transfer Agreement (“Agreement” or “SMTA 1”) has been \ndeveloped. \nArticle 1. Parties to the Agreement\n1.1\t\nParties to SMTA 1 are limited to influenza laboratories that have been designated or recognized by WHO and have accepted to wo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Contains the Framework's annexes, beginning with Standard Material Transfer Agreement 1, which sets the terms for transferring PIP biological materials within GISRS. It then gives Standard Material Transfer Agreement 2 for transfers to recipients outside GISRS, including manufacturers' commitments to benefit sharing. The articles cover the parties, obligations, intellectual property, liability and dispute settlement, with signature blocks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Advisory Group terms of reference",
      "pageStart": 43,
      "pageEnd": 46,
      "target": "../sections/sec-035-annex-3-advisory-group-terms-of-reference.md",
      "narrative": null,
      "content": "Terms of Reference\n(Adopted by the Intergovernmental Meeting at its resumed session in December \n2008, as amended by the Open-Ended Working Group of Member States on Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines \nand other benefits in April 2011.)\n1. Background and mandate of the Advisory Group\n1.1\t\nThe Interim Statement adopted by WHO Member States attending the session of the Intergovernmental Meeting on Pandemic Influenza Preparedness, \n20–23 November 2007, urged action to develop fair, transparent, and equitable international mechanisms on virus shari",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the terms of reference of the Advisory Group of the Pandemic Influenza Preparedness Framework, as adopted in 2008 and amended in 2011, which is mandated to monitor, assess and report on the sharing of H5N1 and other potentially pandemic influenza viruses and on access to vaccines and other benefits. Its functions include monitoring virus sharing through the WHO Global Influenza Surveillance and Response System, the virus traceability mechanism, laboratory capacity, benefit sharing and the use of contributions, advising the Director-General and submitting an evidence-based annual report. It also specifies 18 members, three from each WHO region, serving three-year terms with annual partial renewal, confidential working procedures under WHO expert committee rules and resources provided by the Director-General.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 4 Guiding Principles for the development of Terms of Reference for current and potential future WHO global influenza surveillance and response system (GISRS) laboratories for H5N1 and other human pandemic influenza viruses",
      "pageStart": 46,
      "pageEnd": 48,
      "target": "../sections/sec-036-40-annex-4-guiding-principles-for-the-developmen.md",
      "narrative": null,
      "content": "Guiding Principles for the development of \nTerms of Reference for current and potential future \nWHO global influenza surveillance and response \nsystem (GISRS) laboratories for H5N1 and other \nhuman pandemic influenza viruses\nThe specific roles, responsibilities and activities conducted by the different WHO \nglobal influenza surveillance and response system (GISRS) laboratories can differ \ndepending on whether they are a National Influenza Centre, a WHO Collaborating \nCentre, an H5 Reference Laboratory or an essential regulatory laboratory. However, \nin the context of pandemic influenza prepare",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 4 of the PIP Framework sets out ten guiding principles for drafting the terms of reference of WHO Global Influenza Surveillance and Response System laboratories working with H5N1 and other potentially pandemic viruses, such as consistency with the Framework and the Standard Material Transfer Agreement, WHO coordination, timely reporting and capacity-building support for Member States. Other principles cover support for vaccine and diagnostic development, involving scientists from submitting laboratories in research, rapid sharing of PIP biological materials using the traceability mechanism, submitting gene sequences to public databases and crediting originating laboratories.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Terms of reference related to work with pandemic influenza preparedness biological materials",
      "pageStart": 48,
      "pageEnd": 68,
      "target": "../sections/sec-037-annex-5-terms-of-reference-related-to-work-with.md",
      "narrative": null,
      "content": "Influenza Preparedness biological materials\nBackground\nThe WHO global influenza surveillance and response system (GISRS) serves as \na global alert mechanism for the emergence of influenza viruses with important \nfeatures, including those with pandemic potential. For activities related to pandemic \ninfluenza, the WHO GISRS includes four complementary categories of institutions \nand laboratories: National Influenza Centres, WHO Collaborating Centres, WHO \nH5 Reference Laboratories and Essential Regulatory Laboratories. The WHO GISRS \nis coordinated by the WHO Global Influenza Programme. Within e",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5 sets out the terms of reference for work with PIP biological materials by the four types of GISRS institutions: National Influenza Centres, WHO Collaborating Centres, H5 Reference Laboratories and essential regulatory laboratories. For each it describes functions such as collecting and sharing specimens and viruses, characterizing them, developing candidate vaccine viruses and reference reagents, and supporting risk assessment. It also covers biosafety, publication and recognition of originating laboratories. The annex ends with the ISBN and WHO contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44796/blocks/figure-img-p068-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 68,
      "pageEnd": 68,
      "target": "../images/img-p068-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode with the number 9789241503082.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
